Start here if you're new
what it is
Cingulate is trying to sell once-daily ADHD tablets that wear off less like a bad alarm clock.
how it gets paid
Last year Cingulate made n/a in revenue.
what just happened
The quarter was another loss, with -$3.60 EPS and -$234K of revenue.
At a glance
C+ balance sheet — struggling to keep the lights on
-$10.20 fy2024 eps est
1.6 beta
~$67M market cap
small cap
xvary composite: 23/100 — weak
What they do
Cingulate is trying to sell once-daily ADHD tablets that wear off less like a bad alarm clock.
One tablet versus multiple doses is the pitch. That matters because routines punish forgetfulness, and ADHD treatment lives inside routines. Cingulate has 13 employees and $0M in TTM revenue, so your money is funding the shot, not the machinery.
How they make money
n/a
annual revenue
The products that matter
ADHD treatment candidate
CTx-1301 (dexmethylphenidate)
FDA action date · may 2026
this is the whole near-term equity story. the NDA is already filed, and the FDA decision in May 2026 is the only obvious path from pre-revenue science project to commercial business.
lead asset
anxiety disorder candidate
CTx-2103
target market · $5.5B
management points to a $5.5B market, but this is earlier-stage and offers no near-term revenue bridge if CTx-1301 slips.
earlier pipeline
drug delivery platform
Precision Timed Release (PTR)
commercial products · 0
the platform is the pitch for once-daily dosing and differentiated release timing. with zero approved products today, its value is still theoretical.
platform risk
Key numbers
$67M
market cap
That is the market’s full price for the company today, which makes every FDA headline matter.
$10.20
fy2024 eps
The company lost $10.20 per share in 2024. That is heavy red ink for a $6 stock.
1.6
beta
A 1.6 beta means the stock tends to move about 60% harder than the market.
$1M
long-term debt
Debt is tiny here. The bigger issue is whether the company can keep funding losses.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $1M (2% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for CING right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The quarter was another loss, with -$3.60 EPS and -$234K of revenue.
Pre-revenue, meaning no real sales yet, is still the story. EDGAR shows the latest quarter at -$234K revenue and the Yahoo trailing EPS at -$5.4, which tells you the losses are still doing the talking.
-$234K
revenue
-$3.60
eps
-$5.40
trailing eps
the number that mattered
The most important number is -$3.60 EPS, because it shows the company is still burning cash while waiting on FDA news.
source: EDGAR SEC filing and Yahoo Finance consensus
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is an FDA rejection or delay for CTx-1301 in May 2026.
med
CTx-1301 misses the finish line
There is one NDA, one near-term catalyst, and no approved product behind it. If the FDA says no or asks for more time, the equity story resets immediately.
100% of the near-term thesis rides on this one filing.
med
Runway meets calendar
Management says cash lasts into Q2 2026, and the FDA date is in May 2026. That is not a cushion. It is a scheduling problem.
A delay beyond Q2 2026 increases the odds of another capital raise or harsher financing terms.
med
The backup plan is not close enough
CTx-2103 targets a $5.5B market, but it is earlier in development and offers no near-term revenue support. The PTR platform also remains unproven commercially.
If CTx-1301 slips, investors are left with science, time, and financing risk — not a second operating engine.
a delay past Q2 2026 would collide with the stated cash runway, and 100% of the near-term equity case still depends on one FDA decision.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
May 2026 FDA decision
This is the one date the stock trades around. Approval turns CTx-1301 into a commercial question. Delay turns it back into a financing question.
risk
Runway into Q2 2026
The company says cash lasts into Q2 2026. You want that statement to get less tight, not more tight, as the FDA date approaches.
metric
Street target spread: $8 to $58
Six analysts cover the stock, and their targets are miles apart. Same company. Same catalyst. Very different assumptions.
trend
Post-financing communication
After a $12M PIPE, the next thing that matters is whether updates get cleaner and more confident or start sounding like bridge financing bought a little time.
Analyst rankings
coverage
6
six analysts cover CING. in human-speak, the stock is followed enough to have opinions on it, but not enough to create comfort.
consensus target
$21.86
that sits far above the current $6 price. the spread says less about precision and more about how binary the setup is.
target range
$8–$58
when the low target is $8 and the high is $58, the street is not agreeing on execution. it is disagreeing on reality.
source: institutional data
Institutional activity
institutional ownership data for CING is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive